This past year brought some sea-changing drugs … as well as a few that didn’t quite work out as planned. Herewith, a highly subjective ranking of the most newsworthy drug launches of 2013: 1. Sovaldi: No drug approved this year had quite the expectations of Gilead Sciences’ (GILD) hepatitis C drug, which the FDA approved on Dec. 6. Although it’s still in the very early days for a drug launch — analysts aren’t expecting annual sales to hit
Gilead Sciences (GILD) reported more positive data from its hepatitis C drug pipeline Wednesday, sending shares up 2% in the stock market today . The data came from three phase-three studies using the recently approved drug sofosbuvir with candidate ledipasvir in patients with genotype 1 of the virus, the most common type. The sustained response rate was well above 90% in all patient groups. Analysts noted that, except among patients who failed
Gilead Sciences’ (GILD) newly approved hepatitis C drug Sovaldi came under fire for its price from pharmacy benefit manager Express Scripts (ESRX) Tuesday, as rival AbbVie (ABBV) reported good data for its competing drug candidate. Gilead’s stock dropped while AbbVie’s rose on the stock market today. Bloomberg reporter Drew Armstrong said on Twitter that Express Scripts’ chief medical officer, Steve Miller, told him that the convenience of